burosumab

burosumab
Trade Name
Orphan Indication Oncogenic osteomalacia
USA Market Approval USA
USA Designation Date 2017-06-15 00:00:00
Sponsor Ultragenyx Pharmaceutical Inc.;60 Leveroni Court, Suite 200;Novato, California, 94949